Supplement: Adjuvant Screening for an inactivated SFTSV Vaccine

点击翻译按钮获取中文摘要

The objective of the contract is to identify novel adjuvants, as part of the NIAID Vaccine Adjuvant Discovery Program and the contractor has developed a portfolio of novel compounds. As part of HHS’ effort to advance the development of vaccines against tick-borne pathogens, the contractor will conduct a formal comparison of adjuvants for a vaccine against severe fever with thrombocytopenia syndrome virus (SFTSV). No such vaccine is currently available, and the contractor has a model system in which the efficacy of such vaccines can be evaluated. SFTS was first reported in 2009 and has since been spreading. It has a fatality rate in humans, an accidental host, of up to 30% and is transmitted not only by ticks, but can also be spread from person to person. In this project, beta-propiolactone-inactivated virus will be formulated with three experimental adjuvants (in comparison to Alum and Addavax) and the efficacy of the vaccines will be evaluated.